Recent clinical trials have shown the new macrolides azithromycin and clarithromycin to be effective in the treatment of nontuberculous mycobacterial disease [1] [2] [3] [4] . Clarithromycin has been studied primarily in the treatment of disseminated Mycobacterium avium complex (MAC) infections in patients with AIDS [5] [6] [7] and has received approval for this indication from the U.S. Food and Drug Administration (FDA). Dosages up to 2,000 mg b.i.d. have been used; the higher doses, however, have been associated with a higher incidence of doselimiting side effects and a higher mortality rate. Among elderly patients with chronic lung disease due to MAC or Mycobacterium abscessus, dosages of 1,000 mg b.i.d, have not been tolerated without a high degree of adverse events [2, 8] ; 11 of 13 patients (85%) in one study discontinued treatment with the drug because of these side effects [2] .
Azithromycin is known to be active in vitro and in murine models against MAC, but only a single report of a clinical treatment trial of the drug using a daily dosage of 500 mg for 4 weeks has been published [4] . A second study has recently been described in abstract form [9] . The drug has been shown to be effective as prophylaxis for disseminated MAC infection when given as 1,200 mg once weekly [10] . Only one study of the use of this drug in the HIV-seronegative population with chronic lung disease has been reported [11] .
Encouraged by our previous experiences with clarithromycin in the treatment of patients with chronic lung disease due to MAC or M. abscessus [1] , we initiated a single-center trial of high-dose (600 mg daily) azithromycin given to HIVseronegative patients with MAC and/or M abscessus lung disease to determine the safety and efficacy of the dosage in this patient population.
Materials and Methods
Patients with chronic mycobacterial lung disease due to MAC or M. abscessus and no risk for HIV disease were recruited from the patient population of the University of Texas Health Center at Tyler. Informed consent was obtained under protocols approved by the facility's Human Subjects Institutional Review Board and by the FDA following an investigational-new-drug application. All patients were enrolled initially into a sponsored single-site, nonrandomized, prospective study of azithromycin for the treatment of nontuberculous mycobacterial pulmonary infections; three patients who were removed from the study were also studied.
The study was open, noncomparative, and nonblinded. Eligible patients were at least 18 years of age. Patients received a 600-mg tablet (a special dosage provided by Pfizer Laboratories, Groton, CT) daily (as monotherapy) on an empty stomach, as directed by the package insert. Patients unable to tolerate the 600-mg dose because of adverse events were switched to a 300-mg daily dose (also provided by Pfizer). Patients with MAC infection received azithromycin monotherapy for 4 months, at the end of which time rifampin or rifabutin, ethambutol, and streptomycin were added to the regimen. Most patients infected with M. abscessus were given a 6-month trial of monotherapy; the addition of doxycycline, sulfamethoxazole, or ciprofloxacin after that time was an option. these patients are shown in table 1 . Twenty-four patients with MAC disease, nine with M. abscessus disease, and six with disease due to both pathogens were evaluated. Selected patients with a history of alcohol and/or drug abuse were tested for HIV and all were negative.
For the majority of patients, HIV testing was not done and HIV status was unknown. However, no patient had common risk factors for HIV-related diseases or had clinically diagnosed AIDS. There were 21 females and 18 males. The majority of the patients were elderly; 34 of the 39 (87%) were > 55 years old and 31 (79%) were >60 years old. The mean age was 66 years. Thirty-two patients (82%) weighed <70 kg, and 10 of 39 patients (26%) weighed <50 kg. The mean weight was 61 kg.
Adverse events were noted in 33 of 39 patients (85%) while they were receiving monotherapy. The majority of these were GI events (32 of 39, or 82%) (table 2). GI symptoms included diarrhea or loose stools (62%), abdominal cramping (41%), anorexia (33%), unusual taste sensation (33%), nausea (28%), vomiting (18%), and other symptoms such as abdominal bloating, gas, and constipation (~IO%). Twenty-two patients had only GI symptoms, while 10 patients had GI symptoms as well as hearing impairment.
The mean serum level in all 22 patients with GI symptoms but no hearing impairment was 0.59 ± 0.36 ,uglmL, which was similar to all values obtained during monotherapy. Of these 22 patients, 13 (59%) had their dosage decreased or therapy discontinued (defined as having severe GI symptoms).
Ten of the 39 patients (26%) complained of hearing impairment during therapy. Five patients denied hearing impairment before the study, while five had preexisting (subjective) hearing Adverse events were assessed for patients receiving the 600-mg daily dose as monotherapy, by means of (1) laboratory tests, (2) a questionnaire, (3) an interview conducted before therapy and repeated at the time of each subsequent visit, and (4) a study coordinator available by telephone 5 days a week. Pretreatment studies of blood urea nitrogen, serum creatinine, serum lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase(ALT), alkaline phosphatase, total bilirubin, and y-glutamyl transpeptidase (GGT) levels were performed, as well as hearing tests (for most patients).
All patients were treated on an outpatient basis and were seen at 2-to 4-week intervals for the first 3 months following initiation of azithromycin therapy and thereafter at monthly intervals. Laboratory tests were repeated at each visit, as were a physical examination and questioning for possible side effects or adverse events. Changes in liver function were considered to have occurred if any hepatic enzyme values rose to twice the upper limit of normal (if initially normal) or twice the baseline values (if initially abnormal). The hearing test was repeated if the patient complained of a subjective decrease in hearing.
Serum azithromycin levels were determined for 37 patients receiving 600 mg/d and 11 patients receiving 300 mg/d. All patients had been receiving therapy for at least 2 weeks. Most of the serum levels were determined 2-5 hours after the dose, although some were determined later after the dose (several patients took their dose before bedtime-as recommended to help decrease gastrointestinal [GI] problems-on the evening before their clinic appointment). Serum levels were determined for 12 of the 600-mg azithromycin recipients while they were receiving combination therapy with rifampin, rifabutin, ethambutol, streptomycin, ciprofloxacin, doxycycline, and/or trimethoprim-sulfamethoxazole.
Serum azithromycin levels were determined by HPLC at BAS Analytics (West Lafayette, IN). Serum samples were frozen at -70°C and were assayed in batches. A standard curve was established with use of set standards, with a linear range of .01 ,ug/mL to 1 ,ug/mL. Validity of standard curves was assessed by assay of quality control samples, run in duplicate at each of three concentrations during each assay run. Changes in drug dosages because of adverse events were based on the clinical judgment of the investigators, because serum levels were available only at a later time.
Group values are expressed herein as mean ± SD. Differences in azithromycin blood levels between various groups, with or without adverse events, were evaluated by means of the Mann-Whitney test. The relationship between azithromycin serum levels and adverse events was evaluated with Fisher's exact test. Significance was assigned with a P value of <.05.
Results
Thirty-nine patients receiving high-dose (600 mg daily) azithromycin were studied. The epidemiological features of impairment that was believed to have worsened during therapy. Of these 10 patients, six underwent paired hearing tests pretherapy and while symptomatic, and three underwent them while symptomatic and after clinical improvement. All showed a change in hearing of at least 10 decibels (dB) on the A scale.
Although occurring at all frequencies, the hearing changes most frequently involved the lower or speech frequencies (500 and 1,000 Hz) (nine of nine patients) and were bilateral and symmetrical. A~20-dB hearing loss was noted in six patients at one of these two frequencies, and a 10-to 15-dB hearing loss was noted in the remaining three. When these losses were added to preexisting hearing thresholds, all patients had a combined hearing threshold of~30 dB (median, 45 dB) at the low frequencies ( figure 1 ).
In general, tinnitus or dizziness was not associated with the acute change in hearing threshold. All 10 patients also had GI symptoms, and all required a dosage alteration or refused further dosings. The mean of 14 azithromycin serum level determinations for nine of these patients was 0.82 ± 0.38 ;:.tg/mL (table 3) .
Eleven patients (28%) reported problems with balance or dizziness. Seven of these patients had a pretreatment history of poor balance or dizziness. in addition, 11 patients (28%) complained of insomnia; four of/these patients had baseline insomnia. None of these adverse events were severe enough to require a dosage adjustment.
•
.~~. . . • Two patients' liver enzyme levels became elevated with use of the 600-mg daily dose. One patient with elevated baseline enzyme levels had been treated with clarithromycin before enrollment in the study. Liver enzyme levels in this patient rose from baseline values of 27 U/L to 82 UIL for AST, 26 U/L to 68 UIL for ALT, and 199 lUlL to 302 lUlL for LDH. Baseline values for alkaline phosphatase and GGT were abnormally high, with values of 323 lUlL and 343 lUlL peaking at 670 lUlL and 634 lUlL, respectively. The total bilirubin level was normal at a range of 0.1-0.3 mg/dL.
Because the enzyme levels continued to rise during azithromycin therapy, even after the dose was decreased, the drug was withdrawn; however, the levels remained elevated. This patient developed progressive respiratory failure and died. At autopsy, histopathologic examination of the liver revealed mild fibrotic changes, which were not considered to have contributed to his death.
A second patient's normal baseline liver enzyme levels strikingly rose during azithromycin therapy. The AST value rose from 20 to 103 U/L, the alkaline phosphatase from 125 to 442 lUlL, and the GGT from 125 to 770 lUlL; the bilirubin value remained normal. The azithromycin therapy was stopped until liver function test values returned to normal (after 5 weeks). Reinstitution of therapy at a dosage of 300 mg daily was well tolerated; liver enzyme levels remained normal.
Of the 33 patients who developed GI problems, hearing impairment, or abnormal liver function, two (6%) discontinued treatment because of severe gastrointestinal complaints and two (6%) discontinued it because of hearing impairment. Another nine patients (23%) were able to tolerate the side effects and kept taking the 600-mg dose. The remaining 20 patients (61%) either had the drug withdrawn until symptoms resolved and Figure 1 . Hearing-threshold change at specified frequencies in nine patientswith mycobacterial lung disease who had subjective hearing changes while receiving treatment with azithromycin (. = value for one patient; I-I = average change at given frequency in hearing threshold, in the more affected ear; dBA = decibels on the A scale). then switched to a 300-mg daily dose or were switched to that lower daily dose without an interruption in therapy.
(82)
With discontinuation of the high-dose therapy and institution of that with the 300-mg daily dose, all 20 of the patients were able to tolerate the antibiotic, without return of the doselimiting adverse events. Table 4 shows the relationship of azithromycin serum levels to adverse events in patients receiving 300-mg and 600-mg doses. Only six patients (15% ofthose studied) reported no adverse events with the 600-mg azithromycin dose. The mean of 19 serum azithromycin levels from these patients was 0.3 ± 0.16 ,ug/mL (P = .001, in comparison with the mean for patients with adverse events; table 3).
A total of 90 serum levels were determined for 37 patients receiving a 600-mg dose, of which 67 levels were for patients Table 4 . Relationship of azithromycin serum levels to adverse events in patients receiving 300-mg and 600-mg daily doses of azithromycin. * Patients were included in the >0.7-JLg/mL category if the serum level exceeded 0.7 JLg/mLat any time. Patients included in the "';;0.7-JLg/mL and "';;0.5-JLg/mL categories had no serum levels exceeding these breakpoints.
t Some patients receiving the 300-mg dose had previously been evaluated while receiving the 600-mg dose. Thirty-four patients receiving the 600-mg dose had serum levels determined during azithromycin monotherapy (67 values). The mean level was 0.6 :::!:: 0.3 ,ug/mL. Nine of the 34 patients had azithromycin serum levels determined during monotherapy and again after addition of other antibiotics to the regimen, including rifampin (five patients) or rifabutin (four patients). The mean serum azithromycin levels were similar before and after the addition of the other drugs (0.4 ,ug/mL vs. 0.3 ,ug/mL; see table 3).
Azithromycin levels for various groups of patients, with and without adverse events, are presented in table 2. Among patients who had azithromycin levels determined during monotherapy vs. during combination therapy, there were no significant differences in the levels. There was a significant difference in azithromycin levels between patients with both GI complaints and hearing impairment and all patients (P = .004).
Azithromycin levels were also significantly higher in those with severe GI complaints than in all patients (P = .003).
There were no significant differences in such levels between all patients and patients with GI symptoms (P > .05) or mild GI symptoms (P > .05). Perhaps more illustrative, patients with no adverse events had significantly lower azithromycin levels than did all patients (P = .001), patients with GI complaints (P = .001), patients with severe GI complaints (P = .0001), patients with mild GI complaints (P = .003), and patients with GI complaints and hearing loss (P = .0001).
Twenty-one serum level determinations for 11 patients receiving 300 mg of azithromycin daily were also made. The mean value of serum levels during therapy with azithromycin alone (0.3 :::!:: 0.09 ,ug/mL) was similar to the mean value during therapy with a combination of antibiotics (0.4 :::!:: 0.3 ,ug/mL; P > .05). Of the 11 patients who had levels determined during the 300-mg dosing, only one (9%) had a level~0.7 ,ug/mL. This patient had continued but tolerable GI symptoms.
The relationships between azithromycin levels and adverse events in patients receiving 600 and 300 mg daily are illustrated in table 4. Although more patients with an azithromycin level of >0.7 ,ug/mL had GI complaints or hearing loss with GI complaints than did patients with levels of :;:;0.7 ,ug/mL and :;:;0.5 ,ug/mL, these differences did not reach statistical significance. One possible explanation for the lack of statistical significance is the small number of samples in each group available for analysis.
In spite of the small sample size, however, there were significantly more patients with no adverse events (fewer patients with any adverse event) among those receiving 600 mg daily with azithromycin levels of :;:;0.7 ,ug/mL and :;:;0.5 ,ug/mL rather than >0.7 ,ug/mL. Not enough patients were available for comparison of patients receiving 300 mg daily whose azithromycin levels were >0.7 ,ug/mL vs. :;:;0.7 ,ug/mL and :;:;0.5 ,ug/mL.
Discussion
Azithromycin is the prototype of an antimicrobial agent in the class of azalides derived from the macrolides [12] . The azalides contain a methyl-substituted nitrogenatom in place of the carbonyl at the 9a position in the macrolide aglycone ring [13, 14] . This modification enhances the chemical stability of the compound by blocking the normal degradation pathway (making azithromycin more resistant to the effects of gastric acid), and more important, it results in an altered pharmacokinetics profile [13] [14] [15] [16] . Since the half-life of azithromycin is >60 hours [17] , tissue concentrations are in excess of serum concentrations by 10-to 100-fold, and these concentrations appear to persist for several days after the dosing stops [13, 18] .
Foulds and colleagues [13] characterized a multicompartmental pharmacokinetic model that describes azithromycin elimination following a single 500-mg dose. The initial tissuedistribution phase results in a rapid decline in drug plasma levels, followed by movement of azithromycin from tissue back into the vascular compartment, elimination by the liver, and transintestinal passage. Most of the drug is not metabolized. What metabolism does occur is primarily by hepatic demethylation [13, 18] . Although short-term oral administration of azithromycin has been shown to increase azithromycin demethylase activity, there appears to be no evidence of hepatic cytochrome P-450 induction or inactivation via cytochrome-metabolite-complex formation [19] .
Studies of adverse events with azithromycin therapy among the elderly have been limited. As part of a clinical trial of almost 4,000 patients, a subset of 451 patients aged 65 years or older (mean age, 72.5 years) was identified. They were given 1.5 g of azithromycin over 5 days for treatment of respiratory or cutaneous infections. Adverse events were noted in 9.3% of the patients, in comparison with an incidence of 12% in the younger patients (mean age, 36 years). The most frequent side effects were GI complaints, including diarrhea, nausea, and abdominal pain. Abnormalities were found in <2% of liver function tests. Fewer than 3% of the patients were withdrawn from the studies because of adverse events [20] . These studies suggest that adverse events are similar in younger and older populations treated with azithromycin.
The current studies demonstrate that the administration of 600 mg of azithromycin daily to elderly HIV-seronegative patients (mean age, 66 years) with chronic mycobacterial lung disease due to M. avium complex or M abscessus results in a higher incidence of side effects than that noted in previous studies using lower doses given over 5 days. Our study is the first detailed report of adverse events associated with a 600-mg daily dosage of azithromycin and the first account of serum concentrations with this dosage. The incidence of adverse events in one previous report [4] on a 500-mg daily dose given for 30 days to patients with AIDS was quite low; the principal adverse events were loose stools and diarrhea. Liver function abnormalities were seen in only two patients with a twofold increase in aminotransferase levels. No serum-level data were provided [4] . In a second study [21] ofa 500-mg dose of azithromycin combined with clofazimine and ethambutol, 3 (14%) of 21 patients developed bilateral hearing impairment, which cleared when the azithromycin was discontinued. Other potential adverse events were not discussed.
Adverse events associated with high-dose azithromycin and clarithromycin (in elderly patients) are not the same. Of the reductions in the 600-mg daily dose of azithromycin that were required for 20 patients, 50% occurred because of temporary hearing impairment, 45% because of GI symptoms, and only one (5%) because of abnormal liver enzyme levels. This finding contrasts with that of a previous study of high-dose clarithromycin, in which 11 (85%) of 13 patients had the high dose discontinued, mainly because of GI symptoms (73%) and abnormal liver enzyme levels (18%); none of the patients had hearing impairment [2] . Overall, five (38%) of the 13 patients receiving high-dose clarithromycin had significantly abnormal hepatic enzyme levels. The reason for these differences is unclear, but they suggest that auditory impairment is more common with use of high-dose azithromycin, while hepatitis is more common with use of high-dose clarithromycin, and GI disturbances are common to both [1, 2, 22] . Similar observations have been made by other authors [21] .
The one patient with abnormal hepatic enzyme levels thought to be due to azithromycin was asymptomatic, and the enzyme level elevations revealed an obstructive or granulomatous pattern similar to that detected by routine testing of eight patients in a previous trial of high-dose clarithromycin (1,000-2,000 mg daily) [22] . The current patient was successfully retreated with the 300-mg daily dosage. Thus, liver disease occurring with azithromycin therapy appears to be a toxic event related to high serum/tissue levels and not to hypersensitivity. Similar findings have been observed with the liver disease related to high-dose clarithromycin; all four patients in one series were successfully retreated with lower doses [22] .
Generally, a wide range of serum azithromycin levels has been reported, likely reflecting the drug's proclivity to partition to the intracellular space in high concentration, with variable redistribution to the serum. In this study, serum levels were not determined at carefully controlled times as in a pharmacokinetic study. Despite this, there was a reasonable relationship between adverse events seen with the 600-mg daily dosage and the measured serum levels of azithromycin.
Previous studies of the usual 5-day course of treatment with azithromycin for bacterial respiratory disease have shown peak serum levels of 0.4 p,g/mL and a low incidence of adverse events [13, 18] . Serum levels ?:-0.7 p,g/mL observed in the current study were generally associated with a higher incidence of adverse events. Eighteen (90%) of 20 patients with azithromycin levels of ?:-0.7 p,g/mL during 600-mg daily dosing required a dosage adjustment or discontinuation of the therapy.
In addition, age and low body weights were associated with greater numbers of adverse events. Fifteen (75%) of this group were aged 55 years or older, and 50% weighed ::::;60 kg. Of the 20 patients given a 300-mg dose, all but one tolerated the dose well. These findings strongly suggest that clinical trials of mycobacterial lung disease in older populations (especially with low body weights) should routinely use no more than a 300-mg dose of azithromycin per day. The reader is reminded, however, that clinical and microbiological outcomes with 300-mg and 600-mg daily dosages have not yet been established and may not be equivalent.
Recent studies with the intravenous form of azithromycin have shown minimal side effects with doses as high as 4 g, suggesting that the GI symptoms likely relate to a direct effect of the drug onthe GI tract rather than high tissue levels [23] .
High tissue levels are likely responsible, however, for the temporary auditory impairment noted in some patients.
Hearing impairment has previously been noted with use of the macrolides [21, 24] . This has generally been associated with high doses of erythromycin (?:-3.0g/d) and, in some cases, preexisting renal impairment. The hearing impairment has usually been bilateral, symmetrical, and reversible.
The small number of cases of erythromycin-related hearing impairment in which audiograms were obtained have involved alteration at all frequencies, but with the greatest changes at speech frequencies rather than high frequencies [24] . In the nine patients in the current study who had symptomatic hearing impairment during azithromycin therapy, hearing changes were comparable to those described with use of erythromycin. They involved speech frequencies (500-1,000 dB) more than high frequencies (6,000-8,000 dB), were bilateral and symmetrical, and resolved with discontinuation of the therapy or a decrease in the dosage of azithromycin. They typically occurred after 4 weeks of treatment and were not related to time of dose. No hearing impairment was seen with use of the 300-mg dose, regardless of duration of therapy, suggesting that total dose was not important. Finally, patients with hearing impairment had the highest mean serum level of any of the groups studied, suggesting that the effect may be related to high tissue levels (presumably within the middle ear).
Note Added in Proof
Since submissionof this study,Tseng et al. [25] reportedprobable or possible reversible hearing impairment in 8 (17%) of 46 HIV-infected patients treated with azithromycin (600 mg/d) as therapyfor disseminated MACor toxoplasmosis. Symptoms developed in 30 to 90 days and resolved in a mean of 4.9 weeks after the drug was discontinued. These findings are comparable to the results in non-HIV-infected patients with chronic lung disease described herein and suggest that any patient receiving prolonged high-dose azithromycin therapy should be monitored for potential ototoxicity.
